Liontrust Investment Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Liontrust Investment Partners’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-30,390	Closed	-$917K	–	210
2025 Q1	$917K	Sell	30,390 -11,231	-27%	-$368K	0.01%	171
2024 Q4	$1.46M	Sell	41,621 -18,023	-30%	-$674K	0.02%	160
2024 Q3	$2.84M	Hold	59,644	–	–	0.04%	136
2024 Q2	$2.84M	Sell	59,644 -228,900	-79%	-$9.39M	0.04%	136
2024 Q1	$12.5M	Buy	288,544 +4,563	+2%	+$217K	0.17%	91
2023 Q4	$14.4M	Sell	283,981 -26,045	-8%	-$1.25M	0.21%	79
2023 Q3	$14.1M	Sell	310,026 -11,548	-4%	-$476K	0.22%	71
2023 Q2	$13.2M	Sell	321,574 -16,027	-5%	-$616K	0.19%	76
2023 Q1	$12.1M	Buy	+337,601	New	+$12.7M	0.18%	90
2022 Q4	–	Sell	-72,269	Closed	-$3.2M	–	216
2022 Q3	$3.2M	Sell	72,269 -122,223	-63%	-$5.15M	0.05%	163
2022 Q2	$7.2M	Buy	+194,492	New	+$7.33M	0.1%	123

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Liontrust Investment Partners's IONS Position: Q2 2025 in Review

Liontrust Investment Partners sold out of Ionis Pharmaceuticals (IONS) in Q2 2025, closing a stake of 30,390 shares — an estimated $917K sold.

Liontrust Investment Partners first reported a position in IONS in Q2 2022 and held it in 11 quarters. The position peaked at $14.4M in Q4 2023. 362 funds tracked by Wall St. Rank hold IONS as of Q2 2025.

Liontrust Investment Partners reported no remaining Ionis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Liontrust Investment Partners sold 30,390 Ionis Pharmaceuticals shares in Q2 2025, an estimated $917K.
Liontrust Investment Partners first reported a position in Ionis Pharmaceuticals in Q2 2022 and held it in 11 quarters.
Liontrust Investment Partners's Ionis Pharmaceuticals position peaked at $14.4M in Q4 2023.
362 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2025.

Based on Liontrust Investment Partners's 13F filing for Q2 2025, filed 19 Aug 2025.